Non-[18F]FDG PET in clinical oncology
- 1 September 2007
- journal article
- review article
- Published by Elsevier in The Lancet Oncology
- Vol. 8 (9) , 822-830
- https://doi.org/10.1016/s1470-2045(07)70274-7
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- 18F-fluorodeoxyglucose PET/CT in cancer imagingClinical Medicine, 2006
- The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and BreastSeminars in Nuclear Medicine, 2006
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug DevelopmentClinical Cancer Research, 2005
- Clinical Applications of PET in OncologyRadiology, 2004
- Is 11 C-choline the most appropriate tracer for prostate cancer?European Journal of Nuclear Medicine and Molecular Imaging, 2004
- F-18 NaF PET for Detection of Bone Metastases in Lung Cancer: Accuracy, Cost-Effectiveness, and Impact on Patient ManagementJournal of Bone and Mineral Research, 2003
- 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PETNuclear Medicine Communications, 2003
- Positron emission tomography of esophageal carcinoma using11C-choline and18F-fluorodeoxyglucoseCancer, 1999
- Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission TomographyJournal of Clinical Oncology, 1999
- Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imagingApplied Radiation and Isotopes, 1999